Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Cellectis SA ( (CLLS) ) is now available.
Cellectis S.A., a clinical-stage biotechnology company specializing in gene-edited allogeneic CAR T-cell therapies and other gene therapies, leverages in-house manufacturing to control the full cell and gene therapy value chain, and is dual-listed on Nasdaq and Euronext Growth. The company is headquartered in Paris with additional operations in New York and Raleigh, N.C.
On May 20, 2026, Cellectis announced that its annual general meeting of shareholders will be held on June 25, 2026, at the Biopark auditorium in Paris at 2:30 p.m. CET. The notice and detailed materials for the meeting are available on the company’s website, underscoring ongoing engagement with investors and governance continuity for its transatlantic shareholder base.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is primarily constrained by weak financial performance—large ongoing losses, meaningful cash burn, and rising leverage. Technical indicators are moderately supportive with neutral momentum and prices holding around key moving averages, but valuation remains pressured due to negative earnings and no dividend data.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company focused on gene editing to develop cell and gene therapies, particularly allogeneic CAR T immunotherapies for oncology. The company pursues an off-the-shelf, ready-to-use CAR T-cell model, supports additional gene therapy indications, and operates an end-to-end value chain with in-house manufacturing from its headquarters in Paris and sites in New York and Raleigh, N.C.
Average Trading Volume: 40,589
Technical Sentiment Signal: Hold
Current Market Cap: $281.2M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.